As compared to Clopidogrel, Prasugrel produces 30 percent less cardiovascular events in diabetics.Research has proven Prasugrel to be more effective in reducing thrombosis of the stent and heart attacks in diabetics suffering from ACS or acute coronary syndromes as compared with Clopidogrel.
Further studies on non-diabetics revealed there was a substantial improvement in patients treated with Prasugrel as against Clopidogrel. Sub group analysis reports show there is a significant reduction in cardio vascular events after ant platelet therapy was given with Prasugrel on patients suffering from diabetes according to Stephen Wiviott, Harvard Medical School’s assistant professor of medicine.
Studies also prove that irrespective of the treatment currently on with the diabetics, results showing reduced cardiovascular activities with prasugrel in them was consistent. Prasugrel is an antiplatelet agent administered orally. Developed by the Eli Lilly and Company and Daiichi Sankyo Company along with Ube Industries Ltds, its Japanese research partner, this drug originated as a treatment option for patients suffering from acute coronary syndrome.
What this drug does is to reduce activation of the platelets. This effectively blocks the surface of the platelets from ADP or adenosine diphosphate receptor. The antiplatelet agents stop platelets from clustering together causing blockage. Heart attacks and strokes are caused by these blockages.
Platelet aggregation of high levels in diabetics treated with insulin as compared with those who were not insulin treated was the result reported by previous studies and as this important finding follows this, it puts forth an interesting potential according to Dr. Wiviott.